Business Description
Profound Medical Corp
NAICS : 621510
SIC : 8689
ISIN : CA74319B1067
Total Employee Number:
162Description
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.74 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.71 | |||||
Beneish M-Score | -1.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19 | |||||
3-Year EBITDA Growth Rate | -2.3 | |||||
3-Year EPS without NRI Growth Rate | 0.5 | |||||
3-Year FCF Growth Rate | -1.4 | |||||
3-Year Book Growth Rate | -9.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 70.32 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.51 | |||||
9-Day RSI | 74.48 | |||||
14-Day RSI | 65.98 | |||||
3-1 Month Momentum % | 1.52 | |||||
6-1 Month Momentum % | -13.84 | |||||
12-1 Month Momentum % | 11.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.56 | |||||
Quick Ratio | 5.71 | |||||
Cash Ratio | 4.74 | |||||
Days Inventory | 549.65 | |||||
Days Sales Outstanding | 129.23 | |||||
Days Payable | 86.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.2 | |||||
Shareholder Yield % | 0.13 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.08 | |||||
Operating Margin % | -202.16 | |||||
Net Margin % | -206.29 | |||||
EBITDA Margin % | -199.52 | |||||
FCF Margin % | -204.67 | |||||
OCF Margin % | -204.67 | |||||
ROE % | -77.63 | |||||
ROA % | -63.4 | |||||
ROIC % | -246.5 | |||||
3-Year ROIIC % | 9327.37 | |||||
ROC (Joel Greenblatt) % | -340.42 | |||||
ROCE % | -70.9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.76 | |||||
PB Ratio | 4.64 | |||||
Price-to-Tangible-Book | 4.64 | |||||
EV-to-EBIT | -5.86 | |||||
EV-to-EBITDA | -5.94 | |||||
EV-to-Revenue | 11.87 | |||||
EV-to-Forward-Revenue | 8.96 | |||||
EV-to-FCF | -5.8 | |||||
Price-to-GF-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 4.96 | |||||
| Price-to-Net-Cash | 7.59 | |||||
Earnings Yield (Greenblatt) % | -17.06 | |||||
FCF Yield % | -14.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PROF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Profound Medical Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.814 | ||
| EPS (TTM) ($) | -1.24 | ||
| Beta | 1.3621 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.43 | ||
| Volatility % | 43.79 | ||
| 14-Day RSI | 65.98 | ||
| 14-Day ATR ($) | 0.325218 | ||
| 20-Day SMA ($) | 6.6745 | ||
| 12-1 Month Momentum % | 11.46 | ||
| 52-Week Range ($) | 3.76 - 8.95 | ||
| Shares Outstanding (Mil) | 36.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Profound Medical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Profound Medical Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 38 days | ||
| General meeting for 2025 | 2026-05-13 | 7.14 (-0.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 7.22 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 7.22 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-22 10:00 | 6.84 (-4.87%) | ||
| Profound Medical CAPTAIN Trial Investor Call | 2026-03-13 11:30 | 5.55 (-0.18%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 16:30 | 7.48 (+2.61%) |
Show
Entries
Profound Medical Corp Frequently Asked Questions
What is Profound Medical Corp(PROF)'s stock price today?
The current price of PROF is $7.29. The 52 week high of PROF is $8.95 and 52 week low is $3.76.
When is next earnings date of Profound Medical Corp(PROF)?
The next earnings date of Profound Medical Corp(PROF) is 2026-08-14 Est..
Does Profound Medical Corp(PROF) pay dividends? If so, how much?
Profound Medical Corp(PROF) does not pay dividend.
Guru Commentaries on NAS:PROF
No articles.
Press Release
Articles on Profound Medical Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers